A Multimodal Assay for Quantitating and Interpreting Changes in Autophagic Flux
- Learn how the Autophagy LC3 HiBiT Reporter Assay can simplify your autophagy research
- Scale up your autophagy analysis with confidence
- See how this autophagy assay's performance compares to other assays in high-throughput
screening formats
Summary
Are you studying autophagy or just getting started and want a simple, add-mix-measure assay? Are you struggling to distinguish autophagy stimulation from late-phase pathway inhibition? Are you screening a large number of compounds and need a quantitative, scalable assay?
While imaging and western blotting are useful approaches for studying autophagy, they can be challenging to interpret and have limited quantitative power. The new Autophagy LC3 HiBiT Reporter Assay enables you to unambiguously discern autophagy inducers from inhibitors with a quantitative, plate-reader based readout. Implementing NanoBiT® and HaloTag®-based technology, our autophagy reporter also allows for imaging and HiBiT blotting modalities to confirm mechanism of action as autophagy modulation, and to discern early- versus late-phase pathway inhibition.
Join this live webinar to learn how the Autophagy LC3 HiBiT Reporter Assay can simplify your autophagy research. You’ll also hear about how Dr. Gary Allenby, CSO and founder of Aurelia Biosciences, benchmarked this autophagy assay against other assays for performance in high-throughput screening formats.
Speakers
Dan Lazar, PhD
Senior Research Scientist
Promega Corporation
Dr. Dan Lazar received his Ph.D. in biological chemistry from the University of Michigan and then completed a postdoctoral fellowship focused on cell signaling at Warner Lambert/Parke-Davis. Subsequently, he was a Team Leader and Senior Scientist at Eli Lilly within the metabolic disease drug-discovery area for well over a decade where he gained extensive experience in the development, validation and implementation of cell-based and biochemical assays for drug discovery. As a Group Leader and Senior Research Scientist at Promega, Dan and his colleagues are principally focused on delivering novel cell-based assays for the quantitative assessment of various aspects of cell health to assist academic and industrial investigators.
Gary Allenby, PhD
Chief Scientific Officer
Aurelia Bioscience, UK
Dr. Gary Allenby has a Ph.D. in reproductive toxicology, and studied the pharmacology of retinoid biology as a post-doc at Hoffmann La Roche, USA. He returned to the UK in 1995 to join the Lead Generation group at Glaxo Wellcome. There he developed cell-based assays for high throughput screening and worked with vendors to validate new technologies for screening and automated HTS. In 2000, he joined the Hit Identification group at AstraZeneca, developing assays for respiratory and inflammatory disease while continuing to work with vendors and automated assays.
In 2011, Dr. Allenby became a founding entrepreneur of Aurelia Bioscience, a pre-clinical contract research organization located in Nottingham, UK. Aurelia Bioscience focuses on developing and implementing innovative cell-based assays for screening, and collaborate with vendors to deliver value-adding data for drug discovery purposes.